Volumetric

HardwareHouston, TX, USAFounded 2018· One of 1757 Hardware companies tracked by AMPulse

Develops vertically integrated 3D bioprinting platforms and materials for manufacturing whole replacement organs.

CEO / Founder: Jordan Miller
Team Size: 11-50
Stage: Acquired
Total Funding: $400M
Latest Round: Acquired
Key Investors: Methuselah Foundation; Methuselah Fund; Y Combinator

Technology & Products

Key Products

Proprietary 3D bioprinting technology for fabricating vascularized tissues and organs.

Technological Advantage

Proprietary biomaterials and systems integrated into 3D Systems' portfolio; spin-out from Rice University.

Differentiation

Value Proposition

Reduces the complexity of organ-scale tissue fabrication through a vertically integrated platform of hardware and proprietary biomaterials.

How They Differentiate

Utilizes SLATE (Stereolithography Apparatus for Tissue Engineering) to achieve 20-50 micron resolution for complex vascularization, significantly outperforming the ~100-200 micron resolution of standard extrusion-based systems like CELLINK BIO X. The process uses visible light and food-dye photoinitiators, reducing cytotoxicity compared to UV-based systems.

Market & Competition

Target Customers

Medical researchers and regenerative medicine companies

Industry Verticals

Medical; Regenerative Medicine

Competitors

CELLINK, Organovo

Growth & Milestones

Growth Metrics

2019 Revenue: $1.5 million; Acquired for up to $400 million in 2021.

Major Milestones

2018: Founded as Rice University spin-out; 2019: Achieved $1.5M revenue; 2020: Participated in Y Combinator; 2021-10: Acquired by 3D Systems for $400M

Notable Customers

United Therapeutics; Lung Biotechnology PBC

https://volumetricbio.com

Why this company matters

Volumetric addresses the challenge of manufacturing whole replacement organs by combining proprietary hardware and biomaterials into a vertically integrated platform. Its SLATE (Stereolithography Apparatus for Tissue Engineering) technology achieves 20-50 micron resolution for complex vascularization, outperforming the 100-200 micron resolution typical of extrusion-based systems like CELLINK BIO X. The process uses visible light and food-dye photoinitiators, reducing cytotoxicity compared to UV-based alternatives.

Target customers include medical researchers and regenerative medicine companies. Notable partners include United Therapeutics and Lung Biotechnology PBC. Volumetric was acquired by 3D Systems in October 2021 for up to $400 million, following participation in Y Combinator and support from the Methuselah Foundation.

The company's competitive moat lies in its integrated hardware-software-biomaterials approach and its SLATE technology's ability to produce organ-scale vascularized tissue. Key risks include the long regulatory and clinical pathway for whole organ replacement and competition from established bioprinting firms like Organovo and CELLINK. The acquisition by 3D Systems provides access to broader distribution and manufacturing resources.